Bailey Pemberton
4 min read
COMPASS Pathways has delivered a powerful 3 year share price gain, even after a recent pullback, and fresh clinical progress on its lead therapy now puts the spotlight on whether that move still lines up with the company’s balance sheet. With the stock last closing at US$10.75, the open question is how much of that price can be grounded in book value rather than story alone.
-
Over the past 3 years the share price has risen about 85.7%, which puts real weight on whether the current valuation can still be anchored to the equity recorded on COMPASS Pathways’ books.
-
Positive Phase 3 results for COMP360 and plans to seek approval in the coming years may support expectations for future revenue and cash flows, which can change how much investors are willing to pay relative to the company’s book value.
-
There is a second opinion on COMPASS Pathways worth weighing. See what analysts think COMPASS Pathways’s shares could be worth.
The issue now is whether that recent share price, after a gain of 64.9% over the past year and a shorter term slide, is adequately supported by COMPASS Pathways’ book value when set against the industry average.
If you are weighing COMPASS Pathways against other opportunities where balance sheet support matters, it can help to compare it with companies in our 32 high quality undervalued stocks
Has COMPASS Pathways Run Too Far on Book Value?
P/B fits COMPASS Pathways because investors are weighing a clinical stage balance sheet against a still loss-making income statement. On this yardstick, the stock trades at about 17.6x book value, which is far above the wider biotech industry’s 1.8x level.
Against closer peers on roughly 5.4x, the gap is still wide and points to an overvalued reading on this metric rather than a modest premium. Despite the positive Phase 3 readout for COMP360 and the path toward an NDA filing, the current P/B implies that a lot of future success is already reflected in the share price compared with both the sector and similar businesses. Investors weighing COMPASS Pathways now need to decide whether the clinical and commercial path justifies that kind of multiple or calls for more caution on how much they pay for each dollar of equity on the balance sheet. Explore the numbers behind COMPASS Pathways’s P/B valuation.
The COMPASS Pathways Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for COMPASS Pathways pick up where the valuation puzzle leaves off and explain which future paths on growth, margins and earnings would need to occur for the shares to be worth significantly more or significantly less than they are today. Instead of stopping at a single model output, they present the underlying assumptions so you can track in real time whether the actual business is moving toward or away from the scenario the valuation relies on, and they are available on Simply Wall St’s Community page.
